The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
DOR and see http://www.futuramedical.com/archive/prelims230317.pdf?=v2
That would appear to be a reasonable assumption on the simple basis of having three separate pain relief doses up for sale instead of one or two, and therefore covers a wider sales spectrum. At present they only have Thornton and Ross as a licence holder for the UK and must now be negotiating with other potential holders, which is why Ken James was recruited and why they have upped the commercial potential accordingly The other point I have raised is that sales for CSD500 will also support the additional costs involved. All good stuff IMO. Cheers
Chariot: I would like to put on record that I have e mailed James Barder and asked if the European manufacturer of CSD500 had been rejected and his reply, received within minutes, was "absolutely not"
It is designed so that it doesn't reflect on the sp, Clearly, this strategy in the case of FUM is to maintain the sp, interpret that how you will, but I dont think they are protecting themselves against a drop, rather the reverse given the potential and the number of license holders. Have a look at PLE in contrast,.with just one license holder that of Recordati.and see which way that sp is going (HK 0575 Regent Pacific). Cheers
What is a 'Block Trade' A block trade, also known as a block order, is an order or trade submitted for the sale or purchase of a large quantity of securities. A block trade involves a significantly large number of equities or bonds being traded at an arranged price between two parties, sometimes outside of the open markets, to lessen the impact on the security price. In general, 10,000 shares of stock, not including penny stocks, or $200,000 worth of bonds are considered a block trade. BREAKING DOWN 'Block Trade' Due to the size of block trades, both on the debt and equities markets, individual investors rarely, if ever, make block trades. In practice, these trades typically occur when large hedge funds and institutional investors buy and sell large sums of bonds and shares in block trades via investment banks and other intermediaries. If a block trade is conducted on the open market, traders must be careful with the trade, seeing as it causes large fluctuations in volume and can impact the market value of the shares or bonds being purchased. Therefore, block trades are usually conducted through an intermediary, rather than the hedge fund or investment bank purchasing the securities normally, as they would for smaller amounts. Read more: Block Trade http://www.investopedia.com/terms/b/blocktrade.asp#ixzz4howx3kY7 Follow us: Investopedia on Facebook
Mathsman: That was then and this is now, 2017 is the year it starts to move on sales, it takes at least five years to get through Phase 1-3 clinical trials and qualifications, plus the shelf life problems, but thats now all history
a)Before MED2002 and Painkillers are ready for market X because Dermasys is too attractive to large Pharma. b)around the time MED2002 and Painkillers are ready for market X because phase 111 tests on products will have completed c)after MED2002 and Painkillers are available on the market d) FUM will not be of interest to large Pharma. e) Any other (stated) option
GCCRa: No I was right and you are wrong, you misunderstood me, I have fully researched this share and know it's a potential sleeping blockbuster, and it's sleeping still, with lots of news coming up this year, but very few are buying and it's a quiet BB. The market has yet to take it up, but it will when CDS500 takes off mid year and sales start coming in. so at the mo there aint much going on now and its very quiet, but not for much longer :-)) Cheers